Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9815416 | 0.84 | RAB9A (0.63) | RAB9AAOC3NPSR1ALDH1A1POLB | |
| SCHEMBL6693126 | 0.83 | KMT2A (0.50) | RAB9AALDH1A1POLBNPC1CYP1A2 | |
| SCHEMBL5535286 | 0.82 | AOC3 (0.51) | RAB9AAOC3NPSR1ALDH1A1POLB | |
| SCHEMBL5535288 | 0.82 | AOC3 (0.51) | RAB9AAOC3NPSR1ALDH1A1POLB | |
| SCHEMBL1948819 | 0.81 | AOC3 (0.58) | RAB9AAOC3NPSR1ALDH1A1POLB | |
| SCHEMBL1696515 | 0.81 | AOC3 (0.62) | RAB9AAOC3NPSR1ALDH1A1POLB | |
| SCHEMBL7685154 | 0.81 | AOC3 (0.51) | AOC3NPSR1ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL8421120 | 0.80 | AOC3 (0.57) | RAB9AAOC3NPSR1ALDH1A1POLB | |
| SCHEMBL10781529 | 0.80 | AOC3 (0.57) | RAB9AAOC3NPSR1ALDH1A1POLB | |
| SCHEMBL15103037 | 0.80 | AOC3 (0.57) | RAB9AAOC3NPSR1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-0297607-B1 | GAMMA-L-GLUTAMYL-4-NITROANILIDE DERIVATIVES AND PROCESS FOR DETERMINING GAMMA-GTP ACTIVITY USING THE SAME | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4851572-A | DIAGNOSIS OF LIVER AND BILE DUCT DISORDERS, ALCOHOLISM | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0297607-A1 | Gamma-L-glutamyl-4-nitroanilide derivatives and process for determining gamma-GTP activity using the same | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | RAB9A 3530/4885AOC3 2247/4885MGLL 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.